Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed ...

Positive high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based ...

Subjects in the trial received 80mg of Tagrisso daily in oral tablet form, combined with a chemotherapy regimen.

AstraZeneca announces positive results from FLAURA2 phase III trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, July 22, 2025, ...

Dr Vamsi Veeramachaneni: Nandita Vijayasimha, Bengaluru Tuesday, July 22, 2025, 08:00 Hrs [IST] Genomic profiling is n ...

AstraZeneca has bolstered the standing of Tagrisso as a first-line treatment for locally advanced or metastatic EGFR-mutated ...

FDA fast-tracks DB-1310, a novel HER3-targeting ADC, offering hope for advanced NSCLC patients with unmet treatment needs.

AstraZeneca (AZ) has shared positive overall survival (OS) results from a late-stage study of its epidermal growth factor ...

Researchers recommended that regulators consider mandating head-to-head trials comparing next-in-class and against existing in-class agents when possible.

The trial's principal investigator Pasi Janne said the results support osimertinib "as standard of care" for EGFR-mutated cancer patients. Janne also noted that AstraZeneca's drug "did not impose any ...

Positive high-level results have been presented from the final overall survival (OS) analysis of the FLAURA2 Phase III trial.